Foghorn Therapeutics (FHTX) Current Leases (2019 - 2026)

Foghorn Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• In Q1 2026, Current Leases fell 79.56% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 79.56% YoY), while the FY2025 annual figure was $923000.0, down 89.82% from the prior year.
• Current Leases for Q1 2026 stood at $1.9 million, up from $923000.0 in the prior quarter.
• The five-year high for Current Leases was $9.1 million in Q1 2025, with the low at $923000.0 in Q4 2025.
• The 5-year median for Current Leases is $6.8 million (2025), against an average of $6.8 million.
• The sharpest annual moves came in 2023 and 2025: Current Leases surged 42.68% in 2023, then sank 89.82% in 2025.
• Foghorn Therapeutics' Current Leases stood at $6.0 million in 2022, then surged by 42.68% to $8.5 million in 2023, then climbed by 6.45% to $9.1 million in 2024, then tumbled by 89.82% to $923000.0 in 2025, then soared by 101.84% to $1.9 million in 2026.
• Business Quant data shows FHTX's Current Leases at $1.9 million in Q1 2026, $923000.0 in Q4 2025, and $6.8 million in Q3 2025.